US-based Syndax Pharmaceuticals and Genentech, a member of the Roche Group, have entered into clinical trial collaboration in cancer immunotherapy combining entinostat and atezolizumab.
Subscribe to our email newsletter
Entinostat is an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)) and atezolizumab is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1).
Syndax chief executive officer Briggs Morrison said: "Clinical development collaborations with industry leaders are an essential element of our strategy to realize the full potential of entinostat and position Syndax at the forefront of next-generation immuno-oncology therapy.
"This collaboration expands our emerging immuno-oncology program into an important new indication. We are looking forward to collaborating with Genentech to study atezolizumab and entinostat in a breast cancer population with few treatment options."
The deal will see Syndax responsible for conducting the Phase Ib/II clinical trial evaluation the safety, tolerability and preliminary efficacy of Syndax’s entinostat in combination with Genentech’s atezolizumab (MPDL3280A) in patients with triple-negative breast cancer.
The agreement also includes a provision where the parties may extend the collaboration to include a Phase III trial as well as additional trials in new indications of mutual interest.